These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30248341)

  • 1. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
    Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
    Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
    Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
    Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.
    Wang Y; Shi C; Lu Y; Poulin EJ; Franklin JL; Coffey RJ
    Am J Pathol; 2015 Apr; 185(4):1123-34. PubMed ID: 25794708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted mobilization of Lrig1
    Wroblewski LE; Choi E; Petersen C; Delgado AG; Piazuelo MB; Romero-Gallo J; Lantz TL; Zavros Y; Coffey RJ; Goldenring JR; Zemper AE; Peek RM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19652-19658. PubMed ID: 31488717
    [No Abstract]   [Full Text] [Related]  

  • 5. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
    Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
    Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
    Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
    Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
    Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
    J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
    Wang Y; Poulin EJ; Coffey RJ
    Br J Cancer; 2013 May; 108(9):1765-70. PubMed ID: 23558895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
    Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
    J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
    Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
    Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
    Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
    Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
    Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
    PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
    Li F; Ye ZQ; Guo DS; Yang WM
    Oncol Rep; 2011 Aug; 26(2):439-46. PubMed ID: 21567105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
    Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
    J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRIG and cancer prognosis.
    Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
    Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
    Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
    J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.
    Del Rio T; Nishitani AM; Yu WM; Goodrich LV
    PLoS Genet; 2013; 9(9):e1003824. PubMed ID: 24086156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
    Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
    Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.